IRs (95% CI) for serious infections according to age and concomitant corticosteroid use
| RA | PsA | UC | PsO | |
| Age | ||||
| <65 years, IR (95% CI) | N=6694 2.2 (2.0 to 2.4) (n=452) | N=711 1.1 (0.7 to 1.7) (n=21) | N=1080 1.7 (1.2 to 2.3) (n=41) | N=3443 1.2 (1.0 to 1.5) (n=108) |
| ≥65 years, IR (95% CI) | N=1270 4.6 (3.8 to 5.4) (n=140) | N=72 1.7 (0.3 to 4.8) (n=3) | N=77 2.1 (0.6 to 5.3) (n=4) | N=220 2.2 (1.1 to 3.9) (n=11) |
| Corticosteroid use | ||||
| Yes, IR (95% CI) | N=4254 3.0 (2.7 to 3.3) (n=390) | N=171 1.6 (0.7 to 3.4) (n=7) | N=523 1.3 (0.7 to 2.2) (n=14) | –* |
| No, IR (95% CI) | N=3710 1.9 (1.6 to 2.1) (n=202) | N=612 1.0 (0.6 to 1.6) (n=17) | N=634 2.0 (1.4 to 2.8) (n=31) | –* |
*Concomitant corticosteroid use was not permitted in the PsO studies.
IR, incidence rate (unique patients with events per 100 patient-years); n, number of patients with the event (events are counted up to 28 days beyond the last dose or to the data cut-off date); N, number of patients per category in the disease cohort; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; UC, ulcerative colitis.